{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:37:18Z","timestamp":1786621038254,"version":"build-2736575974"},"reference-count":70,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondation L\u00e9on Fr\u00e9dericq\u201d","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FNRS-T\u00e9l\u00e9vie","award":["7.8509.19"],"award-info":[{"award-number":["7.8509.19"]}]},{"name":"National Fund for Scientific Research (FNRS), Belgium","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic reprogramming through enhanced glycolysis is a hallmark of cancer that supports tumor progression and promotes protumor immune responses. Methylglyoxal (MG), a reactive by-product of glycolysis, has recently emerged as an oncometabolite implicated in cancer progression and therapy resistance. Our previous work demonstrated that an imbalance between MG production and detoxification by the glyoxalase system, referred to as MG stress, contributes to progression and metastatic dissemination in triple-negative breast cancer (TNBC). However, the impact of MG stress on the tumor immune microenvironment remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using two preclinical breast cancer models, we investigated the relationship between MG stress and immune modulation, with a focus on granulocytic myeloid-derived suppressor cells (g-MDSCs), major mediators of immune evasion. In silico analyses were performed to assess correlations between MG stress-related gene signatures and transcriptional markers of MDSC infiltration in patients with TNBC, as well as associations with anti-programmed cell death protein 1 (PD-1) immunotherapy response in melanoma cohorts. In vivo experiments combined the MG scavenger carnosine with PD-1 blockade in the immunotherapy-resistant 4T1 breast cancer model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MG stress was associated with the expansion of g-MDSCs in breast cancer models. Importantly, MG stress conferred metastatic potential to non-metastatic 67NR breast tumors, potentially through activation of the Nuclear Factor kappa B (NF-\u03baB) pathway, increased granulocyte-macrophage colony-stimulating factor expression, and systemic expansion of g-MDSCs. In silico analyses revealed a positive correlation between MG stress-related gene signature and transcriptional markers of MDSC infiltration in patients with TNBC. Furthermore, this signature distinguished anti-PD-1 responder (low MG stress), from non-responders (high MG stress) in patients with melanoma. Therapeutically, combined targeting of MG stress with carnosine and PD-1 signaling significantly reduced g-MDSC accumulation in tumors, spleens, and lungs, and decreased lung metastatic burden in the 4T1 model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings identify MG stress as a driver of an immunosuppressive tumor microenvironment that may impair immunotherapy efficacy and promote metastatic progression in TNBC. Dual targeting of MG stress and PD-1 signaling represents a promising therapeutic strategy to overcome immune suppression and limit metastasis in immunotherapy-resistant breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014841","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:10:25Z","timestamp":1786619425000},"page":"e014841","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer"],"prefix":"10.1136","volume":"14","author":[{"given":"Victoria","family":"Mohring","sequence":"first","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ancion","sequence":"additional","affiliation":[{"name":"Experimental Pathology, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-3047","authenticated-orcid":false,"given":"Pascale","family":"Hubert","sequence":"additional","affiliation":[{"name":"Experimental Pathology, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lardinois","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bizet","sequence":"additional","affiliation":[{"name":"Institute for Medical Immunology, Free University of Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stern","sequence":"additional","affiliation":[{"name":"GIGA Platforms -Genomics, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude A","family":"Liegeois","sequence":"additional","affiliation":[{"name":"Laboratory of Immunophysiology, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roncarati","sequence":"additional","affiliation":[{"name":"Experimental Pathology, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferman","family":"Agirman","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efma","family":"Maloujahmoum","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bellier","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wissocq","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Julie","family":"Nokin","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-8997","authenticated-orcid":false,"given":"Michael","family":"Herfs","sequence":"additional","affiliation":[{"name":"Experimental Pathology, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Peulen","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-0943","authenticated-orcid":false,"given":"Bassam","family":"Janji","sequence":"additional","affiliation":[{"name":"Tumor Immunotherapy and Microenvironment, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg City, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-7631","authenticated-orcid":false,"given":"Akeila","family":"Bellahcene","sequence":"additional","affiliation":[{"name":"Metastasis Research Laboratory, GIGA Research Institute, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2026081304101314000_14.8.e014841.1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"2026081304101314000_14.8.e014841.2","doi-asserted-by":"publisher","DOI":"10.1006\/brbi.1996.0035"},{"key":"2026081304101314000_14.8.e014841.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.85"},{"key":"2026081304101314000_14.8.e014841.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1993.tb17638.x"},{"key":"2026081304101314000_14.8.e014841.5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semcancer.2017.05.010","article-title":"Methylglyoxal-derived stress: an emerging biological factor involved in the onset and progression of cancer","volume":"49","author":"Bellahc\u00e8ne","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"2026081304101314000_14.8.e014841.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-018-1095-7","article-title":"Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK\/ERK\/SMAD1 pathway activation in breast cancer","volume":"21","author":"Nokin","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026081304101314000_14.8.e014841.7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19375","article-title":"Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis","volume":"5","author":"Nokin","year":"2016","journal-title":"Elife"},{"key":"2026081304101314000_14.8.e014841.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.01.012"},{"key":"2026081304101314000_14.8.e014841.9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/cells12101414","article-title":"Resistance to gemcitabine in pancreatic cancer is connected to methylglyoxal stress and heat shock response","volume":"12","author":"Crake","year":"2023","journal-title":"Cells"},{"key":"2026081304101314000_14.8.e014841.10","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.005"},{"key":"2026081304101314000_14.8.e014841.11","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","article-title":"Tumor glycolysis, an essential sweet tooth of tumor cells","volume":"86","author":"Paul","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2026081304101314000_14.8.e014841.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3300"},{"key":"2026081304101314000_14.8.e014841.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298571","article-title":"The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy","volume":"14","author":"Mej\u00eda-Guarnizo","year":"2023","journal-title":"Front Immunol"},{"key":"2026081304101314000_14.8.e014841.14","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-026-01750-1","article-title":"Immune checkpoint inhibitors in malignant melanoma: anti-PD-1, anti-CTLA-4 and anti-LAG-3 therapies","volume":"28","author":"Allen-Tejerina","year":"2026","journal-title":"Curr Oncol Rep"},{"key":"2026081304101314000_14.8.e014841.15","doi-asserted-by":"crossref","first-page":"1137464","DOI":"10.3389\/fendo.2023.1137464","article-title":"Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis","volume":"14","author":"Liang","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026081304101314000_14.8.e014841.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"2026081304101314000_14.8.e014841.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.072"},{"key":"2026081304101314000_14.8.e014841.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.004"},{"key":"2026081304101314000_14.8.e014841.19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026081304101314000_14.8.e014841.20","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13176"},{"key":"2026081304101314000_14.8.e014841.21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"2026081304101314000_14.8.e014841.22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41419-019-1922-5","article-title":"The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1\u2013STAT3 signaling pathway","volume":"10","author":"Lin","year":"2019","journal-title":"Cell Death Dis"},{"key":"2026081304101314000_14.8.e014841.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"2026081304101314000_14.8.e014841.24","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040893","article-title":"New insights into the multifaceted role of myeloid-derived suppressor cells (MDSCs) in high-grade gliomas: from metabolic reprogramming, immunosuppression, and therapeutic resistance to current strategies for targeting MDSCs","volume":"10","author":"Lakshmanachetty","year":"2021","journal-title":"Cells"},{"key":"2026081304101314000_14.8.e014841.25","doi-asserted-by":"crossref","first-page":"698532","DOI":"10.3389\/fcell.2021.698532","article-title":"Novel characterization of myeloid-derived suppressor cells in tumor microenvironment","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026081304101314000_14.8.e014841.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01413-x"},{"key":"2026081304101314000_14.8.e014841.27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006555","article-title":"Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026081304101314000_14.8.e014841.28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1061789","article-title":"Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer","volume":"12","author":"Schreier","year":"2022","journal-title":"Front Oncol"},{"key":"2026081304101314000_14.8.e014841.29","doi-asserted-by":"publisher","DOI":"10.1042\/bst0311343"},{"key":"2026081304101314000_14.8.e014841.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2006.06.007"},{"key":"2026081304101314000_14.8.e014841.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.08.005"},{"key":"2026081304101314000_14.8.e014841.32","doi-asserted-by":"publisher","DOI":"10.1186\/bcr77"},{"key":"2026081304101314000_14.8.e014841.33","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eb3358"},{"key":"2026081304101314000_14.8.e014841.34","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.202048666","article-title":"Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer","volume":"50","author":"Tavukcuoglu","year":"2020","journal-title":"Eur J Immunol"},{"key":"2026081304101314000_14.8.e014841.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-019-1189-x","article-title":"Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs","volume":"21","author":"Bosiljcic","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026081304101314000_14.8.e014841.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025"},{"key":"2026081304101314000_14.8.e014841.37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"2026081304101314000_14.8.e014841.38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1108472","article-title":"Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer","volume":"13","author":"Ding","year":"2023","journal-title":"Front Oncol"},{"key":"2026081304101314000_14.8.e014841.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.728.11.2"},{"key":"2026081304101314000_14.8.e014841.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02100","article-title":"The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent","volume":"9","author":"Grasselly","year":"2018","journal-title":"Front Immunol"},{"key":"2026081304101314000_14.8.e014841.41","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2026081304101314000_14.8.e014841.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880959","article-title":"Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors","volume":"13","author":"Cohen","year":"2022","journal-title":"Front Immunol"},{"key":"2026081304101314000_14.8.e014841.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016"},{"key":"2026081304101314000_14.8.e014841.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.02.008"},{"key":"2026081304101314000_14.8.e014841.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.04.002"},{"key":"2026081304101314000_14.8.e014841.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9"},{"key":"2026081304101314000_14.8.e014841.47","doi-asserted-by":"crossref","first-page":"166425","DOI":"10.1016\/j.bbadis.2022.166425","article-title":"Immunometabolism and the modulation of immune responses and host defense: a role for methylglyoxal?","volume":"1868","author":"Zhang","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026081304101314000_14.8.e014841.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410626111"},{"key":"2026081304101314000_14.8.e014841.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.12.004"},{"key":"2026081304101314000_14.8.e014841.50","first-page":"1399","article-title":"Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor","volume":"52","author":"Aslakson","year":"1992","journal-title":"Cancer Res"},{"key":"2026081304101314000_14.8.e014841.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01338-5"},{"key":"2026081304101314000_14.8.e014841.52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00165","article-title":"The engagement between MDSCs and metastases: partners in crime","volume":"10","author":"Trovato","year":"2020","journal-title":"Front Oncol"},{"key":"2026081304101314000_14.8.e014841.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.10.027"},{"key":"2026081304101314000_14.8.e014841.54","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-5336"},{"key":"2026081304101314000_14.8.e014841.55","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-609","article-title":"MMP-9 expression varies according to molecular subtypes of breast cancer","volume":"14","author":"Yousef","year":"2014","journal-title":"BMC Cancer"},{"key":"2026081304101314000_14.8.e014841.56","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"2026081304101314000_14.8.e014841.57","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0622-8"},{"key":"2026081304101314000_14.8.e014841.58","first-page":"1486","article-title":"Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines","volume":"58","author":"Pulaski","year":"1998","journal-title":"Cancer Res"},{"key":"2026081304101314000_14.8.e014841.59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2495"},{"key":"2026081304101314000_14.8.e014841.60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1075114","article-title":"Repeated PD-1\/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer","volume":"5","author":"Mall","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026081304101314000_14.8.e014841.61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12119-7","article-title":"Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death","volume":"7","author":"Nokin","year":"2017","journal-title":"Sci Rep"},{"key":"2026081304101314000_14.8.e014841.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0287-z"},{"key":"2026081304101314000_14.8.e014841.63","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089"},{"key":"2026081304101314000_14.8.e014841.64","doi-asserted-by":"publisher","DOI":"10.1021\/ja406077j"},{"key":"2026081304101314000_14.8.e014841.65","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026081304101314000_14.8.e014841.66","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118"},{"key":"2026081304101314000_14.8.e014841.67","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4324"},{"key":"2026081304101314000_14.8.e014841.68","doi-asserted-by":"crossref","unstructured":"Dube G , Tiamiou A , Bizet M , et al . Methylglyoxal: a novel upstream regulator of DNA methylation. J Exp Clin Cancer Res 2023;42. doi:10.1186\/s13046-023-02637-w","DOI":"10.1186\/s13046-023-02637-w"},{"key":"2026081304101314000_14.8.e014841.69","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr671"},{"key":"2026081304101314000_14.8.e014841.70","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy024"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:10:31Z","timestamp":1786619431000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,13]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/jitc-2026-014841"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014841","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}